Cargando…

Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness

OBJECTIVE: Cardiac diastolic dysfunction (DD) and arterial stiffness are early manifestations of obesity-associated prediabetes, and both serve as risk factors for the development of heart failure with preserved ejection fraction (HFpEF). Since the incidence of DD and arterial stiffness are increasi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aroor, Annayya R., Mummidi, Srinivas, Lopez-Alvarenga, Juan Carlos, Das, Nitin, Habibi, Javad, Jia, Guanghong, Lastra, Guido, Chandrasekar, Bysani, DeMarco, Vincent G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061206/ https://www.ncbi.nlm.nih.gov/pubmed/33882908 http://dx.doi.org/10.1186/s12933-021-01270-1

Ejemplares similares

The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat
por: Habibi, Javad, et al.
Publicado: (2019)

SAT-LB011 Role of Endothelium Epithelial Sodium Channel in Arterial Stiffness
por: Jia, Guanghong, et al.
Publicado: (2019)

Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
por: Aroor, Annayya R., et al.
Publicado: (2018)

Empagliflozin Reverses Oxidized LDL-Induced RECK Suppression, Cardiotrophin-1 Expression, MMP Activation, and Human Aortic Smooth Muscle Cell Proliferation and Migration
por: Chandrasekar, Bysani, et al.
Publicado: (2023)

FRI131 Abrogation Of Transglutaminase 2 In Myeloid Cells Ameliorates Angiotensin II Induced Vascular Stiffness In Female Mice
por: Naz, Huma, et al.
Publicado: (2023)

Sacubitril/valsartan in the treatment of systemic right ventricular failure
por: Zandstra, Tjitske E, et al.
Publicado: (2021)

A narrative review on sacubitril/valsartan and ventricular arrhythmias
por: Wei, Zhaoyang, et al.
Publicado: (2022)

Vascular stiffness in insulin resistance and obesity
por: Jia, Guanghong, et al.
Publicado: (2015)

Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021)

Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes
por: Habibi, Javad, et al.
Publicado: (2017)

Effect of sacubitril/valsartan or valsartan on ventricular remodeling and myocardial fibrosis in perimenopausal women with hypertension
por: Chen, Jianshu, et al.
Publicado: (2023)

Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload
por: Nordén, Einar Sjaastad, et al.
Publicado: (2021)

Amiloride Improves Endothelial Function and Reduces Vascular Stiffness in Female Mice Fed a Western Diet
por: Martinez-Lemus, Luis A., et al.
Publicado: (2017)

SAT-LB97 MiRNA-99a and mTOR2 Mediate Enhanced Endothelial Mineralocorticoid Receptor Signaling-Induced Activation of Sodium Channel and Endothelium Stiffness
por: Jia, Guanghong, et al.
Publicado: (2020)

The Role of Tissue Renin-Angiotensin-Aldosterone System in the Development of Endothelial Dysfunction and Arterial Stiffness
por: Aroor, Annayya R., et al.
Publicado: (2013)

Differential Effects of Sacubitril/Valsartan on Diastolic Function in Mice With Obesity-Related Metabolic Heart Disease
por: Croteau, Dominique, et al.
Publicado: (2020)

Reverse electromechanical modelling of diastolic dysfunction in spontaneous hypertensive rat after sacubitril/valsartan therapy
por: Sung, Yen‐Ling, et al.
Publicado: (2020)

Effect of sacubitril/valsartan on investigator‐reported ventricular arrhythmias in PARADIGM‐HF
por: Curtain, James P., et al.
Publicado: (2022)

Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF
por: Schauer, Antje, et al.
Publicado: (2021)

Implication of low dose sacubitril/valsartan
por: Imamura, Teruhiko
Publicado: (2021)

Eligibility and Usage of Sacubitril/Valsartan in Korea
por: Kim, Jin-Jin, et al.
Publicado: (2019)

Impact of Sacubitril/Valsartan on Patient Outcomes in Heart Failure: Evidence to Date
por: Akbar, Sara, et al.
Publicado: (2020)

Effect of add-on sacubitril/valsartan on the left ventricular hypertrophy of a patient with hypertension
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Insights into implementation of sacubitril/valsartan into clinical practice
por: Martens, Pieter, et al.
Publicado: (2018)

Sacubitril–valsartan in heart failure and multimorbidity patients
por: Rodil Fraile, Raquel, et al.
Publicado: (2018)

Re: Implication of low‐dose sacubitril/valsartan
por: Pandey, Amitabh C., et al.
Publicado: (2021)

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
por: Mustafa, Nor Hidayah, et al.
Publicado: (2022)

Effects of Sacubitril/Valsartan on the Renal Resistance Index
por: Gioia, Margherita Ilaria, et al.
Publicado: (2022)

Short-term effect of sacubitril/valsartan on endothelial dysfunction and arterial stiffness in patients with chronic heart failure
por: Cassano, Velia, et al.
Publicado: (2022)

Sacubitril/valsartan averts post-myocardial infarction ventricular remodeling and preserves heart function
por: Hajra, Adrija, et al.
Publicado: (2019)

Left ventricular output indices and sacubitril/valsartan titration: role of stroke volume index
por: Tolomeo, Paolo, et al.
Publicado: (2022)

Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice
por: Aroor, Annayya R., et al.
Publicado: (2017)

Multi-omic analysis of the cardiac cellulome defines a vascular contribution to cardiac diastolic dysfunction in obese female mice
por: Dona, Malathi S. I., et al.
Publicado: (2023)

Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment
por: Anderson, Sarah L, et al.
Publicado: (2018)

The Diuretic Effect of Sacubitril/Valsartan Might Be Clinically Relevant
por: Beck-da-Silva, Luís, et al.
Publicado: (2019)

Practical guidance on the use of sacubitril/valsartan for heart failure
por: Sauer, Andrew J., et al.
Publicado: (2018)

Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma
por: Andersen, Ulrik Ø, et al.
Publicado: (2020)

Effectiveness of sacubitril–valsartan in cancer patients with heart failure
por: Martín‐Garcia, Ana, et al.
Publicado: (2020)

Renin profiling predicts neurohormonal response to sacubitril/valsartan
por: Vergaro, Giuseppe, et al.
Publicado: (2020)

Haemodynamic effects of sacubitril/valsartan in advanced heart failure
por: Gentile, Piero, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cciaugt0d0bll0su0dl4i8n1mb